Following the introduction of prostate-specific antigen (PSA) screening in the early 1990s, there has been a 50% decline in prostate cancer-specific mortality and more than a 70% decline in the incidence of metastases at diagnosis. 1 Given the recent declines in PSA screening and prostate cancer incidence, we sought to assess the effect of these changes on prostate cancer presentation. Results | As the Table shows, in men younger than 75 years, there was an increase in the proportion of men presenting with distant metastases from 2.7% (95% CI, 2.5%-2.9%) to 4.0% (95% CI, 3.8%-4.2%) and in the proportion presenting with intermediate-and high-grade prostate cancer from 46.3% (95% CI, 45.9%-46.9%) to 56.4% (95% CI, 55.9%-56.9%) (P < .01, respectively). Similarly, in men 75 years or older, there was an increase in the proportion of distant metastases from 6.6% (95% CI, 6.2%-7.0%) to 12.0% (95% CI, 11.2%-12.7%) and intermediate-and high-grade prostate cancer from 58.1% (95% CI, 57.2%-59.0%) to 72% (95% CI, 71%-73%) (P < .01, respectively). Between 2010 and 2013, median PSA at diagnosis increased from 6.0 ng/mL (interquartile range [IQR], 4.6-9.1 ng/ mL) to 6.4 ng/mL (IQR, 4.8-10.0 ng/mL) among men younger than 75 years and increased from 9.0 ng/mL (IQR, 5.8-17.3 ng/ mL) to 9.7 ng/mL (IQR, 6.2-21.0 ng/mL) among men 75 years or older (both P < .01). (To convert PSA to micrograms per liter, multiply by 1.0.) In adjusted analysis ( Figure) , the incidence of distant metastases at diagnosis in men 75 years or older decreased from 2004 to 2011 and increased afterward. No change was observed in men younger than 75 years.
Discussion | This study demonstrates a significant increase in distant metastases at diagnosis in men 75 years or older. The absence of an increase in men younger than 75 years may be due to the US Preventive Services Task Force's recommendation in 2008 against prostate cancer screening in men 75 years or older, followed by its recommendation in 2012 against screening regardless of age. Although Schröeder et al 2 found that the true contamination of PSA screening in the cancer screening trial's control arm approached 90%, rendering the study uninterpretable. Whether the benefits associated with population-based screening outweigh overdiagnosis and overtreatment remains controversial. Nevertheless, to our knowledge, this is the first national, population-based study to demonstrate that the decline in PSA screening has significantly altered prostate cancer presentation. In men 75 years or older, the incidence of metastasis at diagnosis is increasing following nadir in 2011. Moreover, the proportion of men diagnosed with clinically significant cancer (Gleason grade of 7-10) increased significantly. These features are associated with a lower likelihood of cure and higher risk for prostate cancerspecific mortality. Our findings differ from those of Jemal et al, 5 who annually assessed metastases with SEER Summary Stage, the most basic staging system used in cancer registries (it was last updated in 2000). However, clinicians are more likely to understand and use the American Joint Committee on Cancer's TNM Staging System. We used SEER Collaborative Stage, which standardizes across staging systems to improve data quality. 6 We also more granularly assessed quarterly incidence. Moreover, yearly incidence ratio analyses from Jemal et al demonstrate that incidences of distant metastases in 2012 and 2013 were significantly higher than in 2011 among men 75 years or older (incidence ratio approximately equal to 1.13; P < .05), which is consistent with our findings. Our study must be interpreted in the context of the study design. Although we demonstrate an increase in the incidence of distant metastases at diagnosis in men 75 years or older, we did not examine prostate cancer-specific mortality, which requires longer observation before meaningful differences can be discerned. Finally, the categorical age cutoffs presented may not correspond with actual demographic change in screening practices. Weight management strategies for cancer survivors have been gaining a lot of attention, and the relationship between obesity and cancer prognosis is complex. Commonly, BMI is used as the standard measuring tool for classifying patients based on obesity risk and susceptibility to disease. However, there are several important facts that we should consider when recommending weight management using solely BMI. First, it is reasonable to consider that non-Western populations define obesity differently. For example, within Asian-Pacific populations, the cutoff BMI classified as overweight is 23 to less than 25 and obesity is 25 or greater, compared with the WHO definitions of 25 to less than 30 and 30 or greater, respectively. 2 Particularly, Asians have a higher body fat percentage compared with whites of the same age, sex, and BMI, which makes them more susceptible to illnesses such as cardiovascular disease, diabetes, and various cancers associated
